Haksöyler, V. Et Al. 2021. Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.. BIOMARKERS IN MEDICINE , vol.15, no.11 , 851-859.

Haksöyler, V., A, A. B., Tolga, , P, O., E, B., & E, T., (2021). Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.. BIOMARKERS IN MEDICINE , vol.15, no.11, 851-859.

Haksöyler, Veysel Et Al. "Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.," BIOMARKERS IN MEDICINE , vol.15, no.11, 851-859, 2021

Haksöyler, Veysel Et Al. "Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.." BIOMARKERS IN MEDICINE , vol.15, no.11, pp.851-859, 2021

Haksöyler, V. Et Al. (2021) . "Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.." BIOMARKERS IN MEDICINE , vol.15, no.11, pp.851-859.

@article{article, author={Veysel Haksöyler Et Al. }, title={Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.}, journal={BIOMARKERS IN MEDICINE}, year=2021, pages={851-859} }